RGNX Gregory Austin Ciongoli bought REGENXBIO Inc. shares — SEC Form 4BUYREGENXBIO Inc.

The stock is down 15.33% over the last five days and trades 42.19% below its 52-week high of $16.19, despite a 33.14% gain over the last 90 days.

• •Q2 2026 earnings call on August 7, 2026, highlighted progress across the late-stage pipeline.
• •Clear Street warns of a potential cash risk due to the FDA decision delaying the resubmission of the RGX-121 application and a potential voucher.
• •The company faces a second clinical hold on its RGX-121 therapy for Hunter syndrome in 2026.

• •The FDA placed a clinical hold on the RGX-121 trial after detecting asymptomatic findings in spine MRIs, which could delay the resubmission of the application.
• •Short interest is high at 13.14% of the float, amplifying volatility following the recent negative news flow.